Prophylaxis in 10 patients with severe haemophilia A and inhibitor: Different approaches for different clinical situations

Haemophilia

Volumn 15, Issue 1, 2009, Pages 203-209

  Jimenez yuste V ^a   Alvarez, M T ^a   Martin Salces M ^a   Quintana, M ^a   Rodriguez Merchan, C ^a   Lopez Cabarcos, C ^a   Velasco, F ^b   Hernandez Navarro F ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Bypassing agent; Haemophilia; Inhibitors; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CHEMOPROPHYLAXIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HEMARTHROSIS; HEMOPHILIA A; HUMAN; INFANT; MUSCLE BLEEDING; PRIMARY PREVENTION; PRIORITY JOURNAL; RANGE OF MOTION; RETROSPECTIVE STUDY; THROMBOEMBOLISM;

ADULT; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; DRUG COSTS; DRUG EVALUATION; FACTOR VIIA; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; INFANT; ISOANTIBODIES; MALE; RANGE OF MOTION, ARTICULAR; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 63049101789     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01915.x     Document Type: Article

References (37)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
2. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
3. Berntorp E, Shapiro A, Astermark J et al. Inhibitor treatment in haemophilias A and B: Summary statement for the 2006 international consensus conference. Haemophilia 2006; 12: 1-7.
4. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
5. Soucie JM, Cianfrini C, Janco RL et al. Joint range-of-motion limitations among young males with hemophilia: Prevalence and risk factors. Blood 2004; 103: 2467-73.
6. Leissinger CA. Prophylaxis in haemophilia patients with inhibitors. Haemophilia 2006; 12: 67-73.
7. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
8. Hilgartner MW, Makipernaa A, Dimichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261-8.
9. Brackmann HH, Effenberger E, Hess L, Schwaab R, Oldenburg J. NovoSeven in immune tolerance therapy. Blood Coagul Fibrinolysis 2000; 11: S39-44.
10. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 7: 517-22.
11. Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 1126-7.
12. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 2005; 11: 203-7.
13. Kreuz W, Escuriola-Ettinghausen C, Martinez I, Mentzer D, Figura S, Klarmann D. Efficacy and safety of factor VIII inhibitor bypass activity (FEIBA) for long-term prophylaxis in patients with high-responding inhibitors. Blood 2000; 96: 265a abstract 1140.
14. Siegmund B, Richter H, Pollmann H. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: What are the costs, what are the benefits? Haemophilia 2005; 11: 638-41.
15. Dimichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
16. Bryant P, Carr M, Martin E, Sutton J. High dose recombinant activated factor VII in a pediatric patient with factor VIII deficiency and high titer inhibitor. Blood 2003; 102: 104b-5b. (abstract 4128).
17. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007; 13: 249-55.
18. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
19. Morfini M, Auerswald G, Kobelt RA et al. Prophylactic treatment of haemophilia patients with inhibitors: Clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-7.
20. Jimenez-Yuste V, Quintana M, Alvarez MT, Martin-Salces M, Hernandez Navarro F. Primary prophylaxis with rFVIIa in a patient with severe Haemophilia A and inhibitor. Blood Coagul Fibrinol 2008; 19: 719-20.
21. Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: Mode of action. Haemophilia 2004; 10: 3-9.
22. Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999; 5: 11-7.
23. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: Consensus recommendations. Haemophilia 2007; 13: 1-22.
24. Lenk H. The German Registry of immune tolerance treatment in hemophilia -1999 update. Haematologica 2000; 85: 45-7.
25. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
26. Haya S, Lopez MF, Aznar JA, Batlle J. Immune tolerance treatment in haemophilia patients with inhibitors: The Spanish Registry. Haemophilia 2001; 7: 154-9.
27. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 32: 25-32.
28. Berntorp E, Astermark J, Bjorkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: Summary statement. Haemophilia 2003; 9: 1-4.
29. Santagostino E, Gringeri A, Mannucci PM. State of care for hemophilia in pediatric patients. Paediatr Drugs 2002; 4: 149-57.
30. Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia 2006; 12: 54-61.
31. Valentino LA. FEIBA prophylaxis in patients with haemophilia A and inhibitors results in a 95% reduction in bleeding episodes. Haemophilia 2004; 10: 115.
32. Schino M, Centra A, Pisedu G, Sbrighi P. APCC (FEIBA) home treatment prophylaxis in inhibitor haemophilia patients. Haemophilia. 2000; 6: 294. (abstract 37).
33. Escuriola-Ettinghausen C, Martinez-Saguer I, Funk M et al. Long-term prophylaxis with FEIBA® in patients with high-responding inhibitors. J Thromb Haemost 2003; 1: Abstract P1628.
34. Ewing NP. Anamnestic responses in hemophilia patients with inhibitors on continuous prophylaxis with factor eight inhibitor bypassing activity, vapor heated (FEIBA VH). J Thromb Haemost 2005; 3: Abstract P2036.
35. Roberts HR, Monroe DM, III, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41: 101-8.
36. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2007; 14: 39-43.
37. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: The role of the first joint bleed. Haemophilia 2005; 11: 438-43.